Stockscreener 앱 받기
1.16
0.87%
0.01
시간 외 거래:
1.15
-0.01
-0.86%
전일 마감가:
$1.15
열려 있는:
$1.13
하루 거래량:
1.43M
Relative Volume:
0.43
시가총액:
$151.34M
수익:
-
순이익/손실:
$-97.17M
주가수익비율:
-1.5539
EPS:
-0.7465
순현금흐름:
$-85.97M
1주 성능:
-15.33%
1개월 성능:
+19.01%
6개월 성능:
+37.28%
1년 성능:
+0.00%
1일 변동 폭
$1.11
$1.18
1주일 범위
$1.11
$1.40
52주 변동 폭
$0.5062
$1.51
Immunic Inc Stock (IMUX) Company Profile
명칭
Immunic Inc
전화
(332) 255-9818
주소
1200 AVENUE OF THE AMERICAS, NEW YORK
Compare IMUX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMUX
Immunic Inc
|
1.16 | 150.03M | 0 | -97.17M | -85.97M | -0.7465 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Immunic Inc Stock (IMUX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-07 | 개시 | Roth Capital | Buy |
| 2025-09-29 | 개시 | Chardan Capital Markets | Buy |
| 2025-03-25 | 개시 | William Blair | Outperform |
| 2024-11-25 | 개시 | H.C. Wainwright | Buy |
| 2024-09-09 | 재개 | Leerink Partners | Outperform |
| 2024-08-27 | 개시 | B. Riley Securities | Buy |
| 2022-10-21 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-09-19 | 재개 | H.C. Wainwright | Buy |
| 2021-04-15 | 개시 | Aegis Capital | Buy |
| 2021-03-24 | 개시 | JMP Securities | Mkt Outperform |
| 2020-10-02 | 개시 | SVB Leerink | Outperform |
| 2020-08-26 | 개시 | Piper Sandler | Overweight |
| 2020-08-07 | 재개 | ROTH Capital | Buy |
| 2020-07-20 | 개시 | BMO Capital Markets | Outperform |
| 2020-06-05 | 개시 | Wedbush | Outperform |
| 2020-05-11 | 개시 | H.C. Wainwright | Buy |
| 2020-03-25 | 개시 | ROTH Capital | Buy |
| 2019-07-11 | 개시 | Chardan Capital Markets | Buy |
모두보기
Immunic Inc 주식(IMUX)의 최신 뉴스
Immunic at Stifel CNS Forum: Strategic Insights on MS Drug - Investing.com
Immunic Details Vidofludimus Calcium MS Strategy, Phase III Timeline at Leerink Conference - Yahoo Finance
Immunic Inc Stock Operating Data - GuruFocus
Why did IMUX stock surge 33% pre-market today? - MSN
Short Interest in Immunic, Inc. (NASDAQ:IMUX) Rises By 14.5% - MarketBeat
Immunic Stock Under Pressure Amid Financial Changes and Market Reactions - StocksToTrade
Immunic Shares Rise Amid Resilient Strategy In Uncertain Markets - timothysykes.com
Immunic Inc. Faces Slow Recovery Amid Financial Struggles - StocksToTrade
symbol__ Stock Quote Price and Forecast - CNN
Should Extended European Patent Protection for Vidofludimus Calcium Reshape Immunic’s (IMUX) Long-Term Value Proposition? - simplywall.st
New European patent covers all dosing regimens of experimental MS therapy - Multiple Sclerosis News Today
A Look At Immunic (IMUX) Valuation As Reverse Split Proposal And Conference Appearance Draw Attention - simplywall.st
IMUX Stock Price, Quote & Chart | IMMUNIC INC (NASDAQ:IMUX) - ChartMill
Volume Recap: What makes Immunic Inc stock attractive today2026 Closing Moves & Consistent Return Investment Signals - baoquankhu1.vn
Immunic at Leerink Global Healthcare Conference: Strategic Insights on MS Drug - Investing.com Australia
Immunic at Leerink Global Healthcare Conference: Strategic Insights on MS Drug By Investing.com - Investing.com India
Immunic secures European patent for vidofludimus calcium dosing By Investing.com - Investing.com Canada
Small cap wrap: Immunic, AtaiBeckley, Standard Uranium, Trust Stamp… - Proactive Investors
Immunic secures European patent for vidofludimus calcium dosing - Investing.com Nigeria
Immunic (IMUX) Secures Key European Patent for Vidofludimus Calc - GuruFocus
Biopharmaceutical company Immunic, Inc. announced that it has been granted a key European patent, which will provide important protection for the administration regimen related to Vidofludimus calcium. - Bitget
Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium - PR Newswire
Immunic secures European patent for MS drug candidate vidofludimus calcium - Proactive financial news
What makes Immunic Inc. (10VA) stock appealing to growth investorsOil Prices & Real-Time Volume Surge Alerts - Naître et grandir
IMUX Forecast, Price Target & Analyst Ratings | IMMUNIC INC (NASDAQ:IMUX) - ChartMill
IMUX Earnings History & Surprises | EPS & Revenue Results | IMMUNIC INC (NASDAQ:IMUX) - ChartMill
Earnings Update: Whats the analyst consensus on Immunic IncDay Trade & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
HC Wainwright Has Bearish Estimate for Immunic Q1 Earnings - MarketBeat
Deep Track group reports 11.45M-share stake in Immunic (IMUX) - Stock Titan
Immunic, Inc. Announces Participation in Investor Conferences Scheduled for March 2026 - geneonline.com
Dentons Advises Immunic, Inc. on Private Placement and Royalty Transactions - Dentons
IMUX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Immunic to Participate in Investor Conferences in March - The Malaysian Reserve
Immunic to present at healthcare investor conferences in March - Yahoo Finance
Immunic execs line up March investor Q&As and webcasts - Stock Titan
Head to Head Review: Neuphoria Therapeutics and Immunic - National Today
Reverse stock split vote at Immunic (NASDAQ: IMUX) tied to Nasdaq listing - Stock Titan
Multiple Sclerosis Competitive Landscape 2026: 75+ Companies, 80+ Pipeline Therapies, 15+ Key FDA & Clinical Milestones Driving the Future of Multiple Sclerosis Treatment, analyses DelveInsight - Barchart.com
Immunic, Inc.Common Stock (NQ: IMUX - The Chronicle-Journal
H.C. Wainwright cuts Immunic stock price target on share count changes - Investing.com Australia
HC Wainwright Issues Pessimistic Forecast for Immunic (NASDAQ:IMUX) Stock Price - MarketBeat
Aug Opening: Can Immunic Inc sustain earnings growthMarket Volume Summary & Risk Controlled Daily Trade Plans - baoquankhu1.vn
Immunic secures $400M to support late-stage MS trialsICYMI - Yahoo Finance
Immunic (NASDAQ:IMUX) Posts Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
Trails Edge Capital Partners, LP Acquires Significant Stake in I - GuruFocus
BVF group details large Immunic (IMUX) pre-funded and common warrants - Stock Titan
IMMUNIC (IMUX) director Robert Nagel files initial insider Form 3 - Stock Titan
Immunic CEO on $400m financing, phase 3 MS plans - Proactive financial news
Immunic sets stage for phase 3 MS data readout after $400M financing - Proactive financial news
Immunic: Fourth Quarter Financial Overview - Bitget
IMMUNIC, INC. SEC 10-K Report - TradingView
Immunic Inc (IMUX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Immunic Inc 주식 (IMUX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Tardio Jason | President and COO |
Jun 05 '25 |
Buy |
0.79 |
12,512 |
9,884 |
12,512 |
| Vitt Daniel | CEO and Director |
Jun 04 '25 |
Buy |
0.77 |
15,000 |
11,550 |
29,000 |
| Neermann Joerg | Director |
Jun 04 '25 |
Buy |
0.77 |
70,000 |
53,900 |
170,000 |
| Neermann Joerg | Director |
Jun 05 '25 |
Buy |
0.76 |
30,000 |
22,800 |
200,000 |
| Whaley Glenn | Chief Financial Officer |
Jun 03 '25 |
Buy |
0.71 |
45,000 |
32,076 |
95,510 |
| Rudick Richard Alan | Director |
Jun 03 '25 |
Buy |
0.70 |
143,075 |
100,024 |
230,375 |
1.20%
0.06%
자본화:
|
볼륨(24시간):